NCT07038369 2026-03-17
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Phase 1 Active not recruiting
Atavistik Bio, Inc
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Rutgers, The State University of New Jersey
University Health Network, Toronto
M.D. Anderson Cancer Center
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano